0(0%) Volume: 5,930,127 1:01AM EDT| Market Cap : 36.55 B | Enterprise Value : 42.19 B | P/E(TTM) : 45.93 | P/B : 5.05 |
|---|
BSX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BSX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 0.03 |
BSX's Cash-to-Debt is ranked lower than
96% of the 323 Companies in the Global Medical Devices industry. ( Industry Median: 2.54 vs. BSX: 0.03 ) Ranked among companies with meaningful Cash-to-Debt only. |
BSX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 0.17 Max: N/A Current: 0.03 |
| Equity-to-Asset | 0.39 |
BSX's Equity-to-Asset is ranked lower than
81% of the 300 Companies in the Global Medical Devices industry. ( Industry Median: 0.65 vs. BSX: 0.39 ) Ranked among companies with meaningful Equity-to-Asset only. |
BSX'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18 Med: 0.51 Max: 0.83 Current: 0.39 |
| Interest Coverage | 4.66 |
BSX's Interest Coverage is ranked lower than
92% of the 220 Companies in the Global Medical Devices industry. ( Industry Median: 73.23 vs. BSX: 4.66 ) Ranked among companies with meaningful Interest Coverage only. |
BSX'
s Interest Coverage Range Over the Past 10 Years
Min: 0.37 Med: 1.92 Max: 3.22 Current: 4.66 |
| Piotroski F-Score: 6 |
|
| Altman Z-Score: 1.93 |
|
| Beneish M-Score: -2.41 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | 12.36 |
BSX's Operating Margin % is ranked higher than
58% of the 303 Companies in the Global Medical Devices industry. ( Industry Median: 3.45 vs. BSX: 12.36 ) Ranked among companies with meaningful Operating Margin % only. |
BSX'
s Operating Margin % Range Over the Past 10 Years
Min: -53.36 Med: -4.23 Max: 11.86 Current: 12.36 |
| Net Margin % | 9.04 |
BSX's Net Margin % is ranked higher than
60% of the 303 Companies in the Global Medical Devices industry. ( Industry Median: 1.77 vs. BSX: 9.04 ) Ranked among companies with meaningful Net Margin % only. |
BSX'
s Net Margin % Range Over the Past 10 Years
Min: -56.12 Med: -4.56 Max: 5.79 Current: 9.04 |
| ROE % | 11.68 |
BSX's ROE % is ranked higher than
61% of the 295 Companies in the Global Medical Devices industry. ( Industry Median: 2.13 vs. BSX: 11.68 ) Ranked among companies with meaningful ROE % only. |
BSX'
s ROE % Range Over the Past 10 Years
Min: -44.65 Med: -3.5 Max: 5.32 Current: 11.68 |
| ROA % | 4.38 |
BSX's ROA % is ranked higher than
58% of the 324 Companies in the Global Medical Devices industry. ( Industry Median: 0.49 vs. BSX: 4.38 ) Ranked among companies with meaningful ROA % only. |
BSX'
s ROA % Range Over the Past 10 Years
Min: -21.16 Med: -1.48 Max: 2.03 Current: 4.38 |
| ROC (Joel Greenblatt) % | 60.05 |
BSX's ROC (Joel Greenblatt) % is ranked higher than
73% of the 321 Companies in the Global Medical Devices industry. ( Industry Median: 6.15 vs. BSX: 60.05 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
BSX'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -144.7 Med: -14.88 Max: 32.39 Current: 60.05 |
| 3-Year Revenue Growth Rate | 4.60 |
BSX's 3-Year Revenue Growth Rate is ranked lower than
51% of the 239 Companies in the Global Medical Devices industry. ( Industry Median: 5.30 vs. BSX: 4.60 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
BSX'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.5 Med: 4.6 Max: 29 Current: 4.6 |
| 3-Year EBITDA Growth Rate | 14.70 |
BSX's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 210 Companies in the Global Medical Devices industry. ( Industry Median: 6.30 vs. BSX: 14.70 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
BSX'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -71.1 Med: 14.7 Max: 271.1 Current: 14.7 |
| Ray Dalio 50,900 sh (+425.61%) John Paulson 410,000 sh (+336.17%) | Dodge & Cox 382,130 sh (-0.73%) PRIMECAP Management 41,805,050 sh (-1.96%) Mario Gabelli 673,046 sh (-2.14%) Vanguard Health Care Fund 46,520,049 sh (-13.24%) Steven Cohen 1,622,600 sh (-15.31%) Paul Tudor Jones 26,610 sh (-21.72%) Michael Price 700,000 sh (-22.22%) Diamond Hill Capital 3,289,862 sh (-32.36%) Pioneer Investments 1,878,761 sh (-36.59%) Jim Simons 1,884,005 sh (-61.57%) Eaton Vance Worldwide Health Sciences Fund 1,698,025 sh (-56.24%) |
| Joel Greenblatt 99,384 sh (New) David Tepper 550,000 sh (New) Ray Dalio 91,000 sh (+78.78%) Jim Simons 2,625,305 sh (+39.35%) Pioneer Investments 1,941,017 sh (+3.31%) Diamond Hill Capital 3,351,408 sh (+1.87%) PRIMECAP Management 41,920,457 sh (+0.28%) | Michael Price 700,000 sh (unchged) Steven Cohen 500,000 sh (unchged) | Paul Tudor Jones Sold Out Eaton Vance Worldwide Health Sciences Fund Sold Out Dodge & Cox 371,671 sh (-2.74%) Mario Gabelli 653,146 sh (-2.96%) Vanguard Health Care Fund 43,872,669 sh (-5.69%) John Paulson 288,000 sh (-29.76%) Steven Cohen 358,400 sh (-77.91%) |
| Julian Robertson 900,000 sh (New) Caxton Associates 20,100 sh (New) Joel Greenblatt 1,664,082 sh (+1574.40%) David Tepper 3,340,000 sh (+507.27%) Jim Simons 5,726,705 sh (+118.13%) Diamond Hill Capital 3,361,258 sh (+0.29%) | John Paulson Sold Out Steven Cohen Sold Out Ray Dalio Sold Out Pioneer Investments 1,938,677 sh (-0.12%) PRIMECAP Management 41,755,967 sh (-0.39%) Vanguard Health Care Fund 42,272,393 sh (-3.65%) Mario Gabelli 625,559 sh (-4.22%) Dodge & Cox 328,655 sh (-11.57%) Michael Price 500,000 sh (-28.57%) |
| Steven Cohen 1,047,500 sh (New) Eaton Vance Worldwide Health Sciences Fund 936,126 sh (New) Julian Robertson 1,069,500 sh (+18.83%) Pioneer Investments 1,974,820 sh (+1.86%) PRIMECAP Management 42,369,167 sh (+1.47%) | Caxton Associates Sold Out Dodge & Cox 324,255 sh (-1.34%) Vanguard Health Care Fund 41,119,293 sh (-2.73%) Jim Simons 5,305,605 sh (-7.35%) Diamond Hill Capital 3,013,614 sh (-10.34%) Mario Gabelli 551,059 sh (-11.91%) David Tepper 2,264,900 sh (-32.19%) Michael Price 295,000 sh (-41.00%) Joel Greenblatt 24,597 sh (-98.52%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Trades | Impact to Portfolio | Price Range * (?) | Current Price | Change from Average | Current Shares | |
|---|---|---|---|---|---|---|---|---|
| Vanguard Health Care Fund | 2017-06-30 | Reduce -2.73% | 0.06% | $24.42 - $28.25 | $ 26.64 | 1% | 41,119,293 |  |
| David Tepper | 2017-06-30 | Reduce -32.19% | 0.44% | $24.42 - $28.25 | $ 26.64 | 1% | 2,264,900 | |
| Julian Robertson | 2017-06-30 | Add 18.83% | 0.92% | $24.42 - $28.25 | $ 26.64 | 1% | 1,069,500 | |
| Mario Gabelli | 2017-06-30 | Reduce -11.91% | 0.01% | $24.42 - $28.25 | $ 26.64 | 1% | 551,059 | |
| Dodge & Cox | 2017-06-30 | Reduce -1.34% | $24.42 - $28.25 | $ 26.64 | 1% | 324,255 | | |
| Michael Price | 2017-06-30 | Reduce -41.00% | 0.63% | $24.42 - $28.25 | $ 26.64 | 1% | 295,000 | |
| Joel Greenblatt | 2017-06-30 | Reduce -98.52% | 0.52% | $24.42 - $28.25 | $ 26.64 | 1% | 24,597 | |
| Vanguard Health Care Fund | 2017-03-31 | Reduce -3.65% | 0.08% | $21.88 - $25.41 | $ 26.64 | 10% | 42,272,393 | |
| David Tepper | 2017-03-31 | Add 507.27% | 1.14% | $21.88 - $25.41 | $ 26.64 | 10% | 3,340,000 | |
| Joel Greenblatt | 2017-03-31 | Add 1574.40% | 0.5% | $21.88 - $25.41 | $ 26.64 | 10% | 1,664,082 | |
| Julian Robertson | 2017-03-31 | New Buy | 4.22% | $21.88 - $25.41 | $ 26.64 | 10% | 900,000 | |
| Mario Gabelli | 2017-03-31 | Reduce -4.22% | $21.88 - $25.41 | $ 26.64 | 10% | 625,559 | | |
| Michael Price | 2017-03-31 | Reduce -28.57% | 0.53% | $21.88 - $25.41 | $ 26.64 | 10% | 500,000 | |
| Dodge & Cox | 2017-03-31 | Reduce -11.57% | $21.88 - $25.41 | $ 26.64 | 10% | 328,655 | | |
| John Paulson | 2017-03-31 | Sold Out | 0.08% | $21.88 - $25.41 | $ 26.64 | 10% | 0 | |
| Vanguard Health Care Fund | 2016-12-31 | Reduce -5.69% | 0.14% | $20.09 - $23.77 | $ 26.64 | 22% | 43,872,669 | |
| Mario Gabelli | 2016-12-31 | Reduce -2.96% | $20.09 - $23.77 | $ 26.64 | 22% | 653,146 | | |
| David Tepper | 2016-12-31 | New Buy | 0.21% | $20.09 - $23.77 | $ 26.64 | 22% | 550,000 | |
| Dodge & Cox | 2016-12-31 | Reduce -2.74% | $20.09 - $23.77 | $ 26.64 | 22% | 371,671 | | |
| John Paulson | 2016-12-31 | Reduce -29.76% | 0.03% | $20.09 - $23.77 | $ 26.64 | 22% | 288,000 | |
| Joel Greenblatt | 2016-12-31 | New Buy | 0.03% | $20.09 - $23.77 | $ 26.64 | 22% | 99,384 | |
| Vanguard Health Care Fund | 2016-09-30 | Reduce -13.24% | 0.35% | $23.11 - $24.48 | $ 26.64 | 12% | 46,520,049 | |
| Michael Price | 2016-09-30 | Reduce -22.22% | 0.62% | $23.11 - $24.48 | $ 26.64 | 12% | 700,000 | |
| Mario Gabelli | 2016-09-30 | Reduce -2.14% | $23.11 - $24.48 | $ 26.64 | 12% | 673,046 | | |
| John Paulson | 2016-09-30 | Add 336.17% | 0.08% | $23.11 - $24.48 | $ 26.64 | 12% | 410,000 | |
| Dodge & Cox | 2016-09-30 | Reduce -0.73% | $23.11 - $24.48 | $ 26.64 | 12% | 382,130 | |
More recent guru trades are included for Premium Members only!! More recent guru trades are included for USA Subscribe Members only!! What is Peter Lynch Charts )| Industry: | Medical Devices » Medical Devices NAICS: 339112 SIC: 3841 | |
|---|---|---|
| Compare: | NAS:ISRG, NYSE:EW, NYSE:ZBH, NYSE:SYK, NAS:ALGN, NYSE:TFX, NYSE:VAR, NAS:ABMD, NAS:MASI, NAS:IART, NAS:NUVA, NYSE:PEN, NYSE:GMED, NYSE:NVRO, NAS:INGN, NAS:SPNC, NAS:MDXG, NYSE:ITGR, NAS:CNMD, NAS:BABY » details | |
| Traded in other countries: | BSX.Germany, | |
| Headquarter Location: | USA |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PE Ratio | 45.93 |
BSX's PE Ratio is ranked lower than
84% of the 179 Companies in the Global Medical Devices industry. ( Industry Median: 30.71 vs. BSX: 45.93 ) Ranked among companies with meaningful PE Ratio only. |
BSX'
s PE Ratio Range Over the Past 10 Years
Min: 13.87 Med: 40.89 Max: 404.33 Current: 45.93 |
| Forward PE Ratio | 21.19 |
BSX's Forward PE Ratio is ranked higher than
71% of the 49 Companies in the Global Medical Devices industry. ( Industry Median: 25.64 vs. BSX: 21.19 ) Ranked among companies with meaningful Forward PE Ratio only. |
N/A |
| PE Ratio without NRI | 45.93 |
BSX's PE Ratio without NRI is ranked lower than
84% of the 178 Companies in the Global Medical Devices industry. ( Industry Median: 31.10 vs. BSX: 45.93 ) Ranked among companies with meaningful PE Ratio without NRI only. |
BSX'
s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.87 Med: 40.89 Max: 404.33 Current: 45.93 |
| Price-to-Owner-Earnings | 33.68 |
BSX's Price-to-Owner-Earnings is ranked lower than
67% of the 109 Companies in the Global Medical Devices industry. ( Industry Median: 36.31 vs. BSX: 33.68 ) Ranked among companies with meaningful Price-to-Owner-Earnings only. |
BSX'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.58 Med: 43.86 Max: 985.26 Current: 33.68 |
| PB Ratio | 5.05 |
BSX's PB Ratio is ranked lower than
74% of the 291 Companies in the Global Medical Devices industry. ( Industry Median: 2.92 vs. BSX: 5.05 ) Ranked among companies with meaningful PB Ratio only. |
BSX'
s PB Ratio Range Over the Past 10 Years
Min: 0.59 Med: 1.45 Max: 5.32 Current: 5.05 |
| PS Ratio | 4.22 |
BSX's PS Ratio is ranked lower than
64% of the 290 Companies in the Global Medical Devices industry. ( Industry Median: 3.32 vs. BSX: 4.22 ) Ranked among companies with meaningful PS Ratio only. |
BSX'
s PS Ratio Range Over the Past 10 Years
Min: 1.02 Med: 2.22 Max: 4.45 Current: 4.22 |
| Price-to-Free-Cash-Flow | 117.36 |
BSX's Price-to-Free-Cash-Flow is ranked lower than
81% of the 110 Companies in the Global Medical Devices industry. ( Industry Median: 32.13 vs. BSX: 117.36 ) Ranked among companies with meaningful Price-to-Free-Cash-Flow only. |
BSX'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.21 Med: 20.81 Max: 220 Current: 117.36 |
| Price-to-Operating-Cash-Flow | 50.17 |
BSX's Price-to-Operating-Cash-Flow is ranked lower than
81% of the 135 Companies in the Global Medical Devices industry. ( Industry Median: 19.50 vs. BSX: 50.17 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. |
BSX'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.75 Med: 15.92 Max: 62.72 Current: 50.17 |
| EV-to-EBIT | 43.36 |
BSX's EV-to-EBIT is ranked lower than
93% of the 177 Companies in the Global Medical Devices industry. ( Industry Median: 24.67 vs. BSX: 43.36 ) Ranked among companies with meaningful EV-to-EBIT only. |
BSX'
s EV-to-EBIT Range Over the Past 10 Years
Min: -2577.3 Med: -3.7 Max: 25838 Current: 43.36 |
| EV-to-EBITDA | 27.56 |
BSX's EV-to-EBITDA is ranked lower than
86% of the 183 Companies in the Global Medical Devices industry. ( Industry Median: 17.99 vs. BSX: 27.56 ) Ranked among companies with meaningful EV-to-EBITDA only. |
BSX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -680.1 Med: 8.9 Max: 242.5 Current: 27.56 |
| Current Ratio | 0.75 |
BSX's Current Ratio is ranked lower than
88% of the 319 Companies in the Global Medical Devices industry. ( Industry Median: 2.64 vs. BSX: 0.75 ) Ranked among companies with meaningful Current Ratio only. |
BSX'
s Current Ratio Range Over the Past 10 Years
Min: 0.52 Med: 1.56 Max: 7.77 Current: 0.75 |
| Quick Ratio | 0.51 |
BSX's Quick Ratio is ranked lower than
90% of the 319 Companies in the Global Medical Devices industry. ( Industry Median: 1.92 vs. BSX: 0.51 ) Ranked among companies with meaningful Quick Ratio only. |
BSX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.33 Med: 1.2 Max: 6.29 Current: 0.51 |
| Days Inventory | 144.19 |
BSX's Days Inventory is ranked lower than
55% of the 285 Companies in the Global Medical Devices industry. ( Industry Median: 128.08 vs. BSX: 144.19 ) Ranked among companies with meaningful Days Inventory only. |
BSX'
s Days Inventory Range Over the Past 10 Years
Min: 113.61 Med: 133.18 Max: 164.78 Current: 144.19 |
| Days Sales Outstanding | 60.49 |
BSX's Days Sales Outstanding is ranked higher than
60% of the 273 Companies in the Global Medical Devices industry. ( Industry Median: 68.17 vs. BSX: 60.49 ) Ranked among companies with meaningful Days Sales Outstanding only. |
BSX'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.51 Med: 61.98 Max: 66.79 Current: 60.49 |
| Days Payable | 55.01 |
BSX's Days Payable is ranked higher than
50% of the 258 Companies in the Global Medical Devices industry. ( Industry Median: 54.45 vs. BSX: 55.01 ) Ranked among companies with meaningful Days Payable only. |
BSX'
s Days Payable Range Over the Past 10 Years
Min: 21.66 Med: 35.22 Max: 67.31 Current: 55.01 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.00 |
BSX's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 226 Companies in the Global Medical Devices industry. ( Industry Median: -4.10 vs. BSX: -1.00 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
BSX'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.9 Med: -1 Max: 4.6 Current: -1 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 2.84 | ||
| Price-to-Median-PS-Value | 1.90 |
BSX's Price-to-Median-PS-Value is ranked lower than
87% of the 275 Companies in the Global Medical Devices industry. ( Industry Median: 1.01 vs. BSX: 1.90 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
BSX'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48 Med: 1.48 Max: 4.29 Current: 1.9 |
| Earnings Yield (Greenblatt) % | 2.31 |
BSX's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 323 Companies in the Global Medical Devices industry. ( Industry Median: 1.25 vs. BSX: 2.31 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
BSX'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -34.3 Med: -1.3 Max: 9.1 Current: 2.31 |
| Forward Rate of Return (Yacktman) % | 42.51 |
BSX's Forward Rate of Return (Yacktman) % is ranked higher than
95% of the 125 Companies in the Global Medical Devices industry. ( Industry Median: 8.78 vs. BSX: 42.51 ) Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only. |
BSX'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.1 Med: 6.9 Max: 16.1 Current: 42.51 |
| Revenue (TTM) (Mil) $ | 8,713.00 |
|---|---|
| EPS (TTM) $ | 0.58 |
| Beta | 0.91 |
| Short Percentage of Float | 0.95% |
| 52-Week Range $ | 19.67 - 28.51 |
| Shares Outstanding (Mil) | 1,372.13 |
| Dec17 | Dec18 | Dec19 | |
|---|---|---|---|
| Revenue (Mil $) | 8,904 | 9,494 | 10,137 |
| EPS ($) | 1.26 | 1.40 | 1.53 |
| EPS without NRI ($) | 1.26 | 1.40 | 1.53 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | 13.20% | ||
| Dividends per Share ($) | |||
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP